The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | MRD testing should be more widely available
Gareth Morgan, MD, PhD, FRCP, FRCPath, from the University of Arkansas for Medical Sciences, Little Rock, AR, gives a brief overview of the importance of minimal residual disease (MRD) in both research and the clinic, emphasizing that MRD testing should be more widely available and used. This video was recorded at the 23rd congress of European Haematology Association (EHA) 2018, held in Stockholm, Sweden.
